Reporting Period

As a general rule, this Report covers the activities of facilities in Japan from April 1, 2016 to March 31, 2017, and the activities of overseas facilities from January 1, 2016 to December 31, 2016. (Certain sections of this Report contain details of activities and initiatives both prior to and after these identified reporting periods.)

Reporting Coverage

This report covers all places of business operated by consolidated subsidiaries of Astellas Pharma Inc. in Japan and all production facilities overseas as well as the principal places of business in Europe and the United States of America. However, the scope of reporting may differ depending in the item. Accordingly, details of the scope covered are identified on an individual basis in instances where a discrepancy arises.

In addition, certain environmental data includes the results of activities of subcontractors because the environment and society is affected not only by the Company's own activities but also via the supply chain.

Important Changes in Organization during the Reporting Period

The Kashima R&D Center closed at the end of fiscal 2015 after completion of transferring its operational functions to the Tsukuba Research Center and the Kyoto Suzaku Office. And the operations of the Kiyosu Research Office were transferred to another company. This report does not contain their environmental performance data for fiscal 2016.
In August 2016, the operations of the Norman Plant were transferred to another company. However, the environmental performance track record of this plant is included in this report.

Corporate Data

Company Name Astellas Pharma Inc.
Headquarters 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan
Capital ¥103,001 million (as of March 31, 2016)
Representative Director Kenji Yasukawa (President and Chief Executive Officer)
Foundation 1923
Net Sales ¥1,311,665 million (Consolidated basis, as of March 31, 2017)
Employees 17,202 (Consolidated basis, as of March 31, 2017)
Professional institution affiliation

Japan Business Federation
The Federation of Pharmaceutical
Manufacturers' Associations of Japan
Japan Pharmaceutical Manufacturers Association, etc.

Scope of environmental information report

1.Coverage of the Environmental Action Plan

As a rule, applies to all business bases in Japan and all production bases overseas. The details of the facilities involved are as follows:

Company name Facility Location Function
Astellas Pharma Inc. Nihonbashi Office Chuo-ku, Tokyo Headquarters,Development
Takahagi Chemistry & Technology Development Center Takahagi, Ibaraki Research
Tsukuba Research Center Tsukuba, Ibaraki
Tsukuba Biotechnology Research Center Tsukuba, Ibaraki
Yaizu Pharmaceutical Research Center Yaizu, Shizuoka
Kiyosu Research Office Kiyosu, Aichi
Kashima R&D Center Yodogawa-ku, Osaka
Kyoto Suzaku Office Shimogyo-ku, Kyoto
Branches/Sales Offices 14 branches, 109 sales offices Sales & Marketing
Astellas Pharma Tech Co., Ltd. Nishine Plant Hachimantai, Iwate Manufacturing
Takahagi Technology Center Takahagi, Ibaraki
Yaizu Technology Center Yaizu, Shizuoka
Toyama Technology Center Toyama, Toyama
Takaoka Plant Takaoka, Toyama
Astellas Pharma Technologies Inc. Norman Plant U.S.A
Astellas Ireland Co., Ltd. Dublin Plant Ireland
Kerry Plant
Astellas Pharma Europe B.V. Meppel Plant Netherlands
Astellas Pharma China, Inc. Shenyang Plant China


Note 1) Operating sites throughout this report are in principle identified according to the name of each facility. In instances where there are multiple facilities on the same site, the following names may be applied.

  • Takahagi Facilities (Takahagi Chemistry & Technology Development Center and Takahagi Technology Center)
  • Yaizu Facilities (Yaizu Pharmaceutical Research Center and Yaizu Technology Center)

Note 2) Because of the succession to another company of the business done at the former Fuji Plant on April 1, 2014, we have changed the boundary of reporting from fiscal 2014. In this report, we have deducted all the past data corresponding to the environmental burden of the former Fuji Plant, but have included the former Fuji Plant in calculating the Company's biodiversity index because we cannot deduct the former Fuji Plant's contribution to net sales from the total. To confirm the accumulated data up to fiscal 2013, which includes the performance of the former Fuji Plant, please refer to the past environmental reports available on the Astellas website. (

2. Facilities Outside the Coverage of Environmental Action Plan

Principal office buildings and research R&D Centers operated by the consolidated subsidiaries listed below:

  • Astellas US LLC (U.S.A.)
  • Astellas Pharma Europe Ltd. (U.K.)
  • Astellas Pharma Europe B.V. (Netherlands)
  • Agensys, Inc. (U.S.A.)
  • Astellas Research Institute of America LLC (U.S.A.)

and office buildings used by sales companies in the Americas, EMEA (Europe, the Middle East and Africa including NIS countries), and the Asia and Oceania regions

Methods for Calculating Performance Data

Methods for Calculating Energy Consumption and GHGs

Type Conversion Coefficients
Calorific value CO2 emissions
Electricity 9.97 GJ/MWh 0.531 tons/MWh *1
Fuel oil 39.1 GJ/kiloliter 2.71 tons/kiloliter
Kerosene 36.7 GJ/kiloliter 2.49 tons/kiloliter
LPG 50.8 GJ/ton 3.00 tons/ton
LNG 54.6 GJ/ton 2.70 tons/ton
City gas 45.0 GJ/thousand m3N 2.24 tons/thousand m3N
Diesel oil 37.7 GJ/kiloliter 2.58 tons/kL
Gasoline 34.6 GJ/kiloliter 2.32 tons/kL
Purchased thermal energy 1.36 GJ/GJ 0.057 tons/GJ


  Electricity *2 Steam
Norman Plant 0.486 tons/MWh -
Dublin Plant,
Kerry Plant
0.425 tons/MWh -
Meppel Plant 0.473 tons/MWh -
Shenyang Plant 0.681 tons/MWh 0.091 tons/GJ


*1 For CO2 emissions calculations in fiscal 2016, we have used the coefficient for fiscal 2015, because at the time of the release (June 2016) of our Japanese Environmental Report, the Electric Power Council for a Low Carbon Society's latest CO2 emission coefficient was unavailable.

*2 The coefficient by country is announced by the International Energy Agency (IEA). It is used to evaluate the Environmental Action Plan. For details of the coefficients used to calculate GHG emissions, see the COemission coefficient accompanying the end-use electricity under Climate Change Mitigation Measures.

*3 In converting the amount of power generated by renewable energy sources such as solar and wind into energy value in Joule, we have used a conversion rate of 3.6 MJ per 1 kWh.

Calculation Method for Scope 3 Emissions